Li Ling, Ma Gui-Xia, Si Zhuang-Li, Wang Peng, Yuan Hui-Li, Ma Wang, Gao Tian-Hui
Department of Palliative Care and Hospice Care, the Ninth People's Hospital of Zhengzhou City, Zhengzhou 450053, China.
Department of Gynecology, the First People's Hospital of Zhengzhou City, Zhengzhou 450000.
Zhen Ci Yan Jiu. 2018 Oct 25;43(10):657-60. doi: 10.13702/j.1000-0607.170853.
To explore the efficacy of moxibustion combined with medication in the treatment of refractory nausea and vomiting and quality of life (QOL) in advanced cancer patients.
A total of 266 advanced cancer patients with nausea and vomiting were randomly assigned to Metoclopramide group (M group, ＝70), Metoclopramide plus Haloperidol group (MH group, ＝65), moxibustion ＋ M group (＝63), and moxibustion ＋ MH group (＝68). Moxibustion was applied to bilateral Zusanli (ST 36), and Guanyuan (CV 4), Qihai (CV 6) for 20 min every time, twice a day for 2 weeks. The Rhodes' Index of nausea, Vomiting and Retching (INVR) was used for assessing the state of these symptoms in duration, frequency and severity (40 points), the 24-item Hamilton Depression Rating Scale (HAMD, 0－76 points) was employed to measure the patients' depression severity, and the Functional Assessment of Cancer Therapy-General (FACT-G, including physical, social/family, emotional, and functional dimensions, 27 items, 108 points) was adopted to measure the cancer patients' QOL.
Following the treatment, the INVR and HAMD scores were significantly decreased in the M, MH, moxibusion＋M and moxibustion＋MH groups in comparison with their own pretreatment (<0.05) and were significantly lower in the moxibustion＋MH group than in the M, MH and moxibustion＋M groups (<0.05). The FACT-G scoring outcomes showed that the scores of physical well-being, emotional well-being, and total score of QOL were significantly higher in the MH, moxibustion＋M and moxibustion＋MH groups than in the M group, and were significantly higher in the moxibustion＋MH group than in the MH and moxibustion＋M groups (<0.05). No significant differences were found between the MH and moxibustion＋M groups in the INVR and HAMD scores, and in the scores of physical well-being, emotional well-being and total score of QOL (>0.05)．.
Moxibustion plus Metoclopramide and Haloperidol can relieve refractory nausea and vomiting, and better depression and QOL in advanced cancer patients, being worthy of popularization in clinical practice.
探讨艾灸联合药物治疗晚期癌症患者难治性恶心呕吐的疗效及生活质量（QOL）。
将266例伴有恶心呕吐的晚期癌症患者随机分为甲氧氯普胺组（M组，n＝70）、甲氧氯普胺加氟哌啶醇组（MH组，n＝65）、艾灸＋M组（n＝63）和艾灸＋MH组（n＝68）。艾灸双侧足三里（ST 36）、关元（CV 4）、气海（CV 6），每次20分钟，每日2次，共2周。采用罗兹恶心、呕吐和干呕指数（INVR）评估这些症状的持续时间、频率和严重程度（满分40分），采用24项汉密尔顿抑郁量表（HAMD，0－76分）测量患者的抑郁严重程度，采用癌症治疗功能评价通用量表（FACT-G，包括生理、社会/家庭、情感和功能维度，共27项，满分108分）测量癌症患者的生活质量。
治疗后，M组、MH组、艾灸＋M组和艾灸＋MH组的INVR和HAMD评分较各自治疗前均显著降低（P<0.05），且艾灸＋MH组显著低于M组、MH组和艾灸＋M组（P<0.05）。FACT-G评分结果显示，MH组、艾灸＋M组和艾灸＋MH组的生理健康、情感健康及生活质量总分均显著高于M组，且艾灸＋MH组显著高于MH组和艾灸＋M组（P<0.05）。MH组与艾灸＋M组在INVR和HAMD评分以及生理健康、情感健康和生活质量总分方面差异无统计学意义（P>0.05）。
艾灸联合甲氧氯普胺和氟哌啶醇可缓解晚期癌症患者的难治性恶心呕吐，改善抑郁症状及生活质量，值得临床推广应用。
